Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (February 2024)
31 slides from Maat Pharma's investor presentation, February 2024
Slide 1: Enhancing Survival through Microbiome Innovation
Ma fat ——J MaaT Pharma rd Enhancing Survival through Microbionte ry fe y * Innovation ° 2 sears
Slide 2: Disclaimer
MaaT Pharma Disclaimer This document has been prepared by Maa Pharma (the “Company*) andis for informationandbackgroundpurposesonly. While the information contained herein has been preparedin good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors g
Slide 3: A late-stage clinical biotech, leading the way in Microbiome therapies in oncology
MaaT Pharma February24 08 . ss . . . . . _ MaaT Pharma: A late-stage clinical biotech, leading the way in Microbiome therapies in oncology la > A LEADER Listed on Euronext (MAAT.PA) global leader in the development of Microbiome Ecosystem Therapies \ in oncology to enhance patient survival ZG Founde
Slide 4: Host-Microbiota Interactions are Critical for a Functional Immune System
MaaT Pharma Host - Microbiota Interactions are Critical for a Functional Immune System A rich and diversified gut ecosystem actively modulates the immune system functionality A diversified microbiome contributes to the education and modulation of our immune system throughout life Bacterial richness
Slide 5: Low High Intermediate
1,00 0,75 0,50 * * 0,25 0,00 0 200 400 600 Low High Intermediate
Slide 6: A Step-by-Step Increasing Value Creation Strategy
MaaT Pharma, February 24 A Step-by-Step Increasing Value Creation Strategy Backed by Leading Capabilities in Microbiome Drug Candidate Production 4 Driving near-term value with the donor-derived MET-N platform POOLING microbiota ggat Progressing next-generation co-cultured scalable MET-C platform ©
Slide 7: Rapid build up to target blockbuster markets
4 > MaaT Pharma February 24 o7 Rapid build up to target blockbuster markets x & MaaT03X é : : MaaT034 Multiple Fields re) ~1 to 5b€! MaaT033 ~ 1 _ - MaaT013 2) 500m€ ~200mé€! Spe. Ecosystem For Improvement of sur Spe. Indication 'PYS EUS, US
Slide 8: Cutting-edge Research Engine Powered by Metagenomics and AI-driven Candidate Selections
>» MaaT Pharma February 24 08 Cutting-edge Research Engine Powered by Metagenomics x and Al-driven Candidate Selections —— i >) iA DATA i Healthy Selected Native Therapeutics donors MET-N XR / () . ‘Op i Leading discovery and Al-driven platform tC - Leading Platform AI ENGINE ; Y{ pata }—+) forMicro
Slide 9: A robust and balanced pipeline allowing for regular milestones
MaaT Pharma, Arobust and balanced pipeline allowing for regular milestones February 24 og Platform Program Indication Preclinical Phase! Phase ll Phase lll Upcoming milestone aGvHD ©PD EMAyFDA ? GI-ORR mid-24 Short Term Milestones M2aTOIS lO PoC Melanoma > Results H2.24/ H1.25 MET-N <4 HSCT ODDEMA P
Slide 10: Driving near-term value with the donor-derived MET-N platform
Driving near-term value with the donor- derived MET-N platform
Slide 11: Microbiome Restoration with MaaT013: A Maximum-Density Product
MaaT Pharma, Febi 1 Microbiome Restoration with MaaT0O13: A Maximum-Density Product * for Fast Engraftment in Acute Situations C > Characteristics GE Administration Available Clinical Data + Curative approach PP Efficacy evaluation in EAP + MaaT013 has received Orphan Drug Designation from FDA and E
Slide 12: Aims to Enhance Survival in Patients with Steroid & Ruxolitinib Resistant aGVHD
MaaT013 Aims to Enhance Survival in Patients with Steroid & Ruxolitinib * Resistant aGVHD through Gut Microbiota Restoration Intestinal dysbiosis is associated with higher mortality in hemato-oncology ! Chemotherapy Antibiotics > Irradiation > Immunosuppressors 50% cee Allogenic Hematopoietic Stem C
Slide 13: ARES, a pivotal Phase 3 trial to treat aGVHD in 3rd line
MaaT Pharma ARES, a pivotal Phase 8 trial to treat AGVHD in 3" line showing ~ “high efficacy and low toxicity” as concluded by the DSMB ea Treatment Period D1, 5, 10 Patients > Screening with SR-Gl-aGvHD (D-14 to D-l) Inclusion criteria Refractory or intolerant DI D28 Mé ‘to 2L ruxolitinib ») MaaT01
Slide 14: Early Access Program (EAP) confirms impact on survival
Early Access Program (EAP) confirms impact on survival when primary endpoint is achieved February 24 Global EAP populations GLORR Patients (%) Overall Survival Rate Survival (%) 6mo 12mo 100: { “x, Responders 60 4 uy 74% 54% 75 \ mn aan 7M 56% , “0 504 sl 47% All patients ay 36% 24% 20 26 0 0+ Mcr M
Slide 15: MaaT033 - The oral ecosystem microbiome capsule for adjunctive and maintenance therapy
Ensuring Optimal Microbiota Function: MaaTO33 - The oral ecosystem microbiome capsule for adjunctive and maintenance therapy Pooled microbiota: high-richness, high-diversity, full ecosystem, Characteristics Microbiome Ecosystem Therapy containing Butycore® Administration Oral (a lyophilized capsule)
Slide 16: MaaT033 to ensure optimal gut microbiota to improve survival in patients receiving allo-HSCT
MaaTO33 to ensure optimal gut microbiota to improve survival in patients ‘ receiving allo-HSCT Intestinal dysbiosis is associated with higher mortality in hemato-oncology' = far] e Chemotherapy Antibiotics United States EU5 Japan — Allogenic Hematopoietic > Irradiation Stem Cell Transplantation > Im
Slide 17: Phase 2b PHOEBUS designed to establish MaaT033 as an adjunctive treatment
Phase 2b PHOEBUS designed to establish MaaTO33 as an adjunctive treatment for patients receiving allo-HSCT 387 patients ina study Atleast targeted globally patients dosed pre- Pre allo-HSCT and post- allo- treatment phase HSCT 15-2Idays Neutrophilrecovery Primary endpoint: Study started in of MaaT03
Slide 18: MaaT033 to slow down Amyotrophic Lateral Sclerosis progression
MaaT Pharma February 24 18 MaaT0O33 to slow down Amyotrophic Lateral Sclerosis progression ASO * Amyotrophic Lateral Sclerosis Rationale for Exploratory Utilization of MaaTO33 in ALS > Could affect up to 60,000 patients in US & EU by 20401 ~ Microbiota-Gut-Brain axis has the potential to become the
Slide 19: Progressing next-generation co-cultured donor independent scalable MET-C platform
Progressing next- generation co-cultured donor independent scalable MET-C platform MET-C
Slide 20: MET-C product generation is driven by predictive AI and proprietary validation
vworerore ED reonn2e 20 MET-C product generation is driven by predictive Al and by state-of-the-art x proprietary in vitro and in vivo validation In silico Data Drug discovery Drug development Indication-specific Donor independent drug candidates Clinical & host ecosystem candidate parameters data I
Slide 21: MaaT034 - Donor-Independent, Full Ecosystem Synthetic Microbiota
February 24 21 Boosting Cancer Therapy: MaaT034 - Ground-breaking, Donor-Independent, Full ~* Ecosystem Synthetic Microbiota to Optimize Immune Checkpoint Inhibitor Treatment C > Characteristics (© 02 Administration Development Program First clinical batches manufactured expected in H2.2024 First in
Slide 22: A diverse gut microbiome increases survival in patients receiving Immune Checkpoint Inhibitors
4a Feb A diverse gut microbiome increases survival in patients receiving Immune Checkpoint Inhibitors (ICI) 22 Higher microbiome richness —> better response rate to ICI in patients with metastatic melanoma Proportion surviving Progression-free — High Intermediate 1.0 Low 0.5: if 0. to} 200 400 600 F
Slide 23: Proof of concept study with MaaT013 to improve ICI response
OY MaaT Pharma February 24 23 . . _ Proof of concept study with MaaTO13 to improve ICI response c MaaTOo13 Bolative ( Ongoing Phase 2a PICASSO trial in collaboration with >) abundai ea Faecalibacteriut Bifidobacterium | ° ‘ich Assistance Publique - Hépitaux de Paris (sponsor) on ~ RCT [MaaT013 + ICI
Slide 24: Envisioning the Future: MaaT03X
MaaT Pharma, February 24 24 Envisioning the Future: MaaTO3X —Tailor-made Al-driven Super-Competent x Synthetic Microbiota for specific indications ~\ Precision Medicine Characteristics Administration Development Program Current indication High richness, co-cultured, Super-competent full ecosystem mi
Slide 25: End-to-End in-house cGMP manufacturing
End-to-End in-house cGMP manufacturing All MET
Slide 26: Building Europe's largest specialized cGMP manufacturing facility for Microbiome Ecosystem Therapies
OY Building Europe’s . largest specialized Fully integrated Manufacturing and development cG M P man ufactu ri ng platform for a streamlined product development, facility for Microbiome See UDEMNE MP sieeSeSs Ecosystem Therapies Building a dedicated 1,600m2 site (expandable) to support demands until
Slide 27: Key
Key
Slide 28: Meaningful milestones in both the near and long term
4a MaaT Pharma, Meaningful milestones in both the near and long term 2024 2025 2026+ MaaT013 (pooled enema) GvHD | EAP long term follow-up EBMT24 GvHD | ARES P3 GFORR mid-24 lO Mela. | PICASSO P2a Results H2.24/H1.25 MaaT013 (pooled enema) GvHD | Final Results (OS) GvHD | Commercial launch MaaT0O83
Slide 29: A Step-by-Step Increasing Value Creation Strategy
MaaT Pharma, February 24 A Step-by-Step Increasing Value Creation Strategy Backed by Leading Capabilities in Microbiome Drug-Candidate Production MET-N MET-C MaaT03X MaaT034 oo MaaT033 CH MaaT013 & Ad bi P. tents ° © Co-cultured caps. Co-cultured capsule atients Pooled enema Pooled capsule Synthetic
Slide 30: Corporate Social Responsibility
MaaT Pharma, Corporate Social x Responsibility MaaT Pharma aims to become the source of Microbiome excellence providing patients with safe and innovative medicines. The Company develops products from sustainable biological matters, driving optimal impact of Microbiome. ®. DEVELOPMENT ase GOALS 2022
Slide 31: Thank you
Thank you [email protected]